After nearly a quarter century, Ton Fang and colleagues1 have provided a keen insight into
the mystery regarding the precise timing of the benefit of riluzole in the treatment of patients …

Comment 386 www. thelancet. com/neurology Vol 17 May 2018 might be an early transient
effect, with other molecular pathways becoming more involved later. Such a proposition …

Clinical trials in amyotrophic lateral sclerosis (ALS) remain stuck in a rut: so many trials, such
high expectations, such disappointing results. Since the trials of riluzole 15 years ago, 1 no …

The Edaravone (MCI-186) ALS 19 Study Group1 reported on the safety and efficacy of
edaravone in a phase 3 study of patients with earlystage amyotrophic lateral sclerosis. The …

The Edaravone (MCI-186) ALS 19 Study Group1 reported on the safety and efficacy of
edaravone in a phase 3 study of patients with earlystage amyotrophic lateral sclerosis. The …

Justified disappointment has followed the publication in The Lancet Neurology of the paper
by Gordon and coworkers, who reported negative results from a large phase III randomised …

Recent studies of amyotrophic lateral sclerosis (ALS) have led to an expectation that
therapies will be found to stop progression of this disease, if not restore lost motor function …

In The Lancet Neurology, Albert Ludolph and colleagues3 report a double-blind, placebo-
controlled, multicentre clinical trial of rasagiline (1 mg/day) as an adjunct treatment to …

Despite the urgent, unmet clinical and economic need for treatment of neurodegenerative
diseases, trials of disease modifying drugs have produced little success. Amyotrophic lateral …

Difficulties and uncertainties in diagnosis, measurement of severity, and staging are
common to all neurodegenerative diseases. In the past 10 years, substantial changes in …